11 March 2015 - The European Commission has approved expanded use of Novo Nordisk’s Tresiba (insulin degludec) to include children and adolescents with diabetes aged one to 17 years.

The green light is based on data from the BEGIN YOUNG 1 trial, to be presented later today at the Diabetes UK Professional Conference in London, showing that Tresiba given once daily in a basal-bolus regimen with insulin aspart effectively maintained long-term glycaemic control.

Tresiba is a long-acting basal insulin analogue first approved in Europe in 2013 for once-daily use in adults with both type I and type II diabetes followed by clearance in May 2014 for combination use with GLP-1 receptor agonists. Conveniently, the drug can be administered at any time of the day and, thereby, is the first to offer diabetics flexibility in the timing of taking insulin.

For more details, go to: http://www.pharmatimes.com/Article/15-03-11/EU_expands_use_of_Novo_s_diabetes_drug_Tresiba.aspx?utm_source=dlvr.it&utm_medium=twitter